Value of Medication Adherence in Polycythemia Vera

Emily A. Knight, RN

Video Categories: Polycythemia Vera

Listen as Emily Knight discusses why medication adherence and educating patients with polycythemia vera is important

Supported through funding from Incyte
July 25, 2018

What the Next Generation of Cancer Biomarkers May Involve

Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.

March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.